# Bioequivalence Study Between SKF101804 Cefixime 200 Milligram (mg)/5 Milliliter (mL) Suspension Versus Cefixime 200 mg/5 mL Suspension Reference Product in Healthy Adult Subjects Under Fasting Conditions

> **NCT03408392** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 28 (actual)

## Conditions studied

- Infections, Bacterial

## Interventions

- **DRUG:** Test formulation A
- **DRUG:** Reference formulation B

## Key facts

- **NCT ID:** NCT03408392
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-06
- **Primary completion:** 2018-03-13
- **Final completion:** 2018-03-13
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2020-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03408392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03408392, "Bioequivalence Study Between SKF101804 Cefixime 200 Milligram (mg)/5 Milliliter (mL) Suspension Versus Cefixime 200 mg/5 mL Suspension Reference Product in Healthy Adult Subjects Under Fasting Conditions". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03408392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*